METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR IN INSULIN SIGNALING

To provide a method of treating an insulin receptor disorder (INSR disorder) such as type 1 diabetes mellitus, dyslipidemia, hyperglycemia, hypoglycemia, glucose intolerance, HIV-HAART induced partial lipodystrophy, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD).SOLUTION: The metho...

Full description

Saved in:
Bibliographic Details
Main Authors JOHN LOUIS DIENER, SCHIEBINGER RICK JEROME, GAO JIAPING
Format Patent
LanguageEnglish
Japanese
Published 17.09.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:To provide a method of treating an insulin receptor disorder (INSR disorder) such as type 1 diabetes mellitus, dyslipidemia, hyperglycemia, hypoglycemia, glucose intolerance, HIV-HAART induced partial lipodystrophy, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD).SOLUTION: The method comprises administering, to a patient having the INSR disorder, a therapeutically effective amount of (a) an isolated human FGF21 polypeptide; or (b) an FGF21 protein variant. Preferably, the FGF21 protein variant is Variant 76 or an Fc fusion protein.SELECTED DRAWING: None 【課題】１型糖尿病、脂質異常症、高血糖症、低血糖症、耐糖能異常、ＨＩＶ／ＨＡＡＲＴ誘導性部分型リポジストロフィー、メタボリック症候群、非アルコール性脂肪肝疾患（ＮＡＦＬＤ）等のインスリン受容体障害（ＩＮＳＲ障害）を処置する方法の提供。【解決手段】ＩＮＳＲ障害を有する患者に、治療有効量の（ａ）単離ヒトＦＧＦ２１ポリペプチド；又は（ｂ）ＦＧＦ２１タンパク質変異体を投与するステップを含む方法。前記ＦＧＦ２１タンパク質変異体が変異体７６、又はＦｃ融合タンパク質であることが好ましい。【選択図】なし
Bibliography:Application Number: JP20200094831